Ovarian cancer: Current status and strategies for improving therapeutic outcomes

Cancer Medicine - Tập 8 Số 16 - Trang 7018-7031 - 2019
Ashwin Chandra1, Cima Pius2, Madiha Nabeel3, Maya Nair3, Jamboor K. Vishwanatha3, Sarfraz Ahmad4, Riyaz Basha3,1
1Texas College of Osteopathic Medicine, UNT Health Science Center, Fort Worth, TX, USA
2Miami Medical School, Miami, FL, USA
3Graduate School of Biomedical Sciences, UNT Health Science Center, Fort Worth, TX, USA
4AdventHealth Cancer Institute, Orlando, FL, USA

Tóm tắt

AbstractOf all the gynecologic tumors, ovarian cancer (OC) is known to be the deadliest. Advanced‐stages of OC are linked with high morbidity and low survival rates despite the immense amount of research in the field. Shortage of promising screening tools for early‐stage detection is one of the major challenges linked with the poor survival rate for patients with OC. In OC, therapeutic management is used with multidisciplinary approaches that includes debulking surgery, chemotherapy, and (rarely) radiotherapy. Recently, there is an increasing interest in using immunomodulation for treating OC. Relapse rates are high in this malignancy and averages around every 2‐years. Further treatments after the relapse are more intense, increasing the toxicity, resistance to chemotherapy drugs, and financial burden to patients with poor quality‐of‐life. A procedure that has been studied to help reduce the morbidity rate involves pre‐sensitizing cancer cells with standard therapy in order to produce optimal results with minimum dosage. Utilizing such an approach, platinum‐based agents are effective due to their increased response to platinum‐based chemotherapy in relapsed cases. These chemo‐drugs also help address the issue of drug resistance. After conducting an extensive search with available literature and the resources for clinical trials, information is precisely documented on current research, biomarkers, options for treatment and clinical trials. Several schemes for enhancing the therapeutic responses for OC are discussed systematically in this review with an attempt in summarizing the recent developments in this exciting field of translational/clinical research.

Từ khóa


Tài liệu tham khảo

10.3322/caac.21577

10.1007/s12032-017-0960-z

10.1038/nrc2644

10.1186/1479-5876-3-25

10.1007/s10585-009-9264-9

10.1038/nm1230

10.1016/j.ygyno.2006.06.032

10.1016/j.ygyno.2005.08.038

10.2217/14796694.2.6.733

10.1515/cclm-2013-0151

10.1002/uog.19174

10.1002/cncr.22594

10.1016/S0197-2456(00)00098-2

10.1016/j.bbrc.2018.11.001

10.1056/NEJMcp0901926

Shah CA, 2009, Influence of ovarian cancer risk status on the diagnostic performance of the serum biomarkers mesothelin, HE4, and CA125, Cancer epidemiology, biomarkers & prevention: a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive, Oncology, 18, 1365

10.1378/chest.07-0013

10.1158/1078-0432.CCR-05-1477

10.1158/1078-0432.CCR-05-1397

10.1001/jama.2017.21926

10.1158/1078-0432.CCR-16-1859

10.1200/JCO.2014.55.9898

Jaaback K, 2016, Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer, Cochrane Database Syst Rev

10.1200/JCO.2015.61.4776

10.1016/j.ygyno.2011.09.011

10.1093/annonc/mdx754

10.1016/S0140-6736(03)13718-X

10.1080/02841860151116420

10.1038/bjc.1998.710

10.1200/JCO.2000.18.17.3084

10.1200/JCO.2006.06.0913

10.1007/s00280-008-0909-1

10.1200/JCO.2007.13.6606

10.1038/nrc822

10.1158/1078-0432.CCR-07-0362

Eliopoulos AG, 1995, The control of apoptosis and drug resistance in ovarian cancer: influence of p53 and Bcl‐2, Oncogene, 11, 1217

10.1038/sj.onc.1210220

10.1038/cdd.2011.158

10.1186/s13048-015-0130-x

10.1200/JCO.2007.15.7693

10.1007/s007950100017

10.1002/ijc.20598

10.1158/0008-5472.CAN-04-4567

10.1002/cncr.23972

10.1002/ijc.2910580507

10.1038/nrc3205

10.1038/nrm1261

10.1200/JCO.2011.37.7929

10.1093/jnci/djr093

10.1038/srep38502

10.1016/j.ejca.2005.08.006

Johnson SW, 1997, Increased platinum‐DNA damage tolerance is associated with cisplatin resistance and cross‐resistance to various chemotherapeutic agents in unrelated human ovarian cancer cell lines, Can Res, 57, 850

Stavrovskaya AA, 2000, Cellular mechanisms of multidrug resistance of tumor cells, Biochemistry, 65, 95

10.1038/sj.onc.1206953

10.1016/j.canlet.2005.04.035

10.1186/s13048-016-0278-z

10.1634/theoncologist.8-5-411

10.1126/science.1360704

10.5732/cjc.011.10329

10.1073/pnas.162491399

10.1124/mol.106.022624

10.1124/mol.109.063172

10.5306/wjco.v7.i1.106

10.1016/j.cell.2010.02.027

10.1158/0008-5472.CAN-09-3427

Maliepaard M, 1999, Overexpression of the BCRP/MXR/ABCP gene in a topotecan‐selected ovarian tumor cell line, Can Res, 59, 4559

10.1016/j.bcp.2011.03.024

10.1007/s10555-007-9042-6

10.1016/S0092-8674(00)81683-9

10.1172/JCI200320530

10.1016/j.cell.2011.02.013

10.1038/sj.onc.1207128

Kajiyama H, 2007, Chemoresistance to paclitaxel induces epithelial‐mesenchymal transition and enhances metastatic potential for epithelial ovarian carcinoma cells, Int J Oncol, 31, 277

10.1038/nrc2620

10.3747/co.19.895

10.1158/1078-0432.CCR-10-2325

10.1158/0008-5472.CAN-05-2123

10.1002/1878-0261.12091

10.4103/0976-9668.82318

10.1146/annurev.immunol.22.012703.104803

10.1146/annurev-immunol-031210-101324

10.3390/cancers10080244

10.1016/j.coi.2009.03.002

10.1016/j.pharmthera.2017.03.008

10.1007/s11864-017-0504-y

10.1073/pnas.1533209100

10.1056/NEJMoa1200690

10.1056/NEJMoa1200694

10.1073/pnas.0509182102

10.1016/j.ygyno.2009.11.020

10.1186/s40661-016-0033-6

10.1055/s-0031-1298281

10.1016/j.ygyno.2010.01.019

10.1016/j.omto.2016.12.001

10.1158/1078-0432.CCR-18-1089

10.1016/j.cell.2017.08.027

10.1158/1078-0432.CCR-10-0041

10.1007/s00262-017-1967-1

10.1126/science.1076514

10.1097/00002371-199410000-00004

10.1080/15384047.2015.1040960

10.1038/sj.mt.6300039

10.1016/j.ccell.2015.06.009

10.1016/bs.ai.2015.12.006

10.1016/j.coi.2009.02.009

10.1158/1078-0432.CCR-06-1183

10.1186/1479-5876-10-157

10.1371/journal.pone.0049829

10.1158/1078-0432.CCR-10-0192

10.1186/1476-4598-13-129

10.1073/pnas.93.1.136

10.3390/ijms19020340

10.1093/annonc/mdx442

Wiggans AJ, 2015, Poly(ADP‐ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer, Cochrane Database Syst Rev, 5

10.1097/CCO.0b013e3283564230

Yellepeddi VK, 2012, Comparative evaluation of small‐molecule chemosensitizers in reversal of cisplatin resistance in ovarian cancer cells, Anticancer Res, 32, 3651

Diab Y, 2017, Targeted therapy in ovarian cancer. A comprehensive systematic review of literature, Anticancer Res, 37, 2809

10.1200/JCO.2018.36.15_suppl.5578

10.1007/s00280-017-3501-8

10.3390/cancers10080242

Thông tin
Thông tin xuất bản

Cancer Medicine

Tập 8 Số 16

7018-7031

Thông tin tác giả